(ENZN) Enzon Pharmaceuticals – Bear of the Day

Enzon Pharma’s (ENZN) first quarter 2011 net loss of $0.07 per share was narrower than the year-ago loss of $0.20 due to substantial cost cutting by management. The discontinuation of the development of PEG-SN38 for mCRC was a major blow to Enzon, leaving it with just one clinical program in mid-stage development and all other programs in early stages of development.

Moreover, royalties from the sales of PegIntron, comprising a substantial part of revenues, have been declining. Recent FDA approval of Incivek and Victrelis can pose strong competition to PegIntron, which could further decline royalties from PegIntron sales.

We have, therefore, downgraded our rating on the stock from Neutral to Underperform. At the end of the first quarter, P/B multiple of the stock was approximately 2.1. Our price target of $9.50 corresponds to a P/B multiple of approximately 1.9.

ENZON PHARMA (ENZN): Free Stock Analysis Report

Zacks Investment Research

About vitalstocks

This is a sample profile field. Vitalstocks is the operating company for Stockbloghub. This will place the picture of the author or company in the profile. Here is another extra line of information.

Comments

Powered by Facebook Comments


Similar Posts: | | Biotechnology | Healthcare

RSS feeds: ENZN | Enzon Pharmaceuticals Inc | Biotechnology | Healthcare |

Other Posts by | RSS Feed for this author